Revelation Biosciences (REVB) Projected to Post Quarterly Earnings on Thursday

Revelation Biosciences (NASDAQ:REVB) will likely be issuing its results before the market opens on Thursday, May 7th. Analysts expect the company to announce earnings of ($1.15) per share for the quarter.

Revelation Biosciences (NASDAQ:REVB) last announced its earnings results on Thursday, February 26th. The company reported ($1.65) earnings per share for the quarter, missing the consensus estimate of ($1.41) by ($0.24). On average, analysts expect Revelation Biosciences to post $-4 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Revelation Biosciences Stock Down 1.1%

NASDAQ:REVB traded down $0.01 during midday trading on Tuesday, reaching $1.07. The stock had a trading volume of 47,349 shares, compared to its average volume of 496,839. The stock has a market cap of $3.97 million, a P/E ratio of -0.02 and a beta of -0.14. The firm has a fifty day simple moving average of $1.22 and a two-hundred day simple moving average of $2.69. Revelation Biosciences has a 12-month low of $0.99 and a 12-month high of $40.08.

Hedge Funds Weigh In On Revelation Biosciences

An institutional investor recently bought a new position in Revelation Biosciences stock. Geode Capital Management LLC acquired a new stake in shares of Revelation Biosciences, Inc. (NASDAQ:REVB) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 34,019 shares of the company’s stock, valued at approximately $27,000. Geode Capital Management LLC owned about 2.15% of Revelation Biosciences as of its most recent SEC filing. Institutional investors and hedge funds own 12.80% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Monday, April 27th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has an average rating of “Sell”.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.